Serum resistin and the risk for hepatocellular carcinoma in diabetic patients

doi:10.3748/wjg.v29.i27.4271

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 27

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8148)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

245

WORD

HTML

3884

Figures (1-2)

726

Tables (1-1)

710

Sum=5615

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

308

Download

924

Sum=1232

Publishing Process of This Article

Item

Count

Browse

301

Download

711

Sum=1012

Jul 21, 2023 (publication date) through Feb 27, 2026

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 21, 2023; 29(27): 4271-4288
Published online Jul 21, 2023. doi: 10.3748/wjg.v29.i27.4271

Serum resistin and the risk for hepatocellular carcinoma in diabetic patients

Mona Mohamed Ibrahim Abdalla

Mona Mohamed Ibrahim Abdalla, Department of Human Biology, School of Medicine, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia

Author contributions: Abdalla MMI collected the data and wrote the paper.

Conflict-of-interest statement: The author declares no conflict of interest for this article.

Corresponding author: Mona Mohamed Ibrahim Abdalla, MSc, PhD, Senior Lecturer, Department of Human Biology, School of Medicine, International Medical University, No. 126, Jln Jalil Perkasa 19, Bukit Jalil 57000, Kuala Lumpur, Malaysia. monamohamed@imu.edu.my

Received: April 26, 2023
Peer-review started: April 26, 2023
First decision: May 27, 2023
Revised: June 11, 2023
Accepted: June 27, 2023
Article in press: June 27, 2023
Published online: July 21, 2023
Processing time: 77 Days and 17.3 Hours

Core Tip

Core Tip: Resistin, a hormone linked to the onset of insulin resistance and diabetes, could be involved in the development and advancement of hepatocellular carcinoma (HCC) in individuals with diabetes. Increased resistin levels have been observed in HCC patients and might be connected to a more severe disease stage and unfavourable prognosis. This review aims to assess the existing literature concerning the possible application of resistin as a biomarker for HCC development and monitoring while investigating the potential processes through which resistin influences HCC’s development and progression in diabetic patients. Gaining a better understanding of these processes may offer valuable insights for the prevention and therapy of this condition.